Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands

Adinda Mieras*, Annemarie Becker-Commissaris, H. Roeline W. Pasman, Anne-Marie M. C. Dingemans, Edith Kok, Robin Cornelissen, Wouter Jacobs, Jan Willem van den Berg, Alle Welling, Brigitte A. H. A. Bogaarts, Lemke Pronk, Bregje D. Onwuteaka-Philipsen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number13210
Number of pages10
JournalEuropean Journal of Cancer Care
Volume29
Issue number2
Early online date21 Dec 2019
DOIs
Publication statusPublished - Mar 2020

Keywords

  • aggressive care
  • cancer treatment
  • chemotherapy
  • end of life
  • metastatic lung cancer
  • Tyrosine Kinase Inhibitors
  • END-OF-LIFE
  • PALLIATIVE CHEMOTHERAPY
  • CARE
  • ONCOLOGY
  • QUALITY
  • OSIMERTINIB
  • GEFITINIB
  • DOCETAXEL
  • NIVOLUMAB
  • ERLOTINIB

Cite this